SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including from sellers, advertising, and subscription services through internationally-focused online stores. The AWS segment is composed of global sales of compute, storage, database, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is trending due to a widespread AWS outage impacting major websites and services, sparking discussions about the internet's reliance on centralized infrastructure. The community is debating the resilience of cloud services and potential alternatives like edge computing. Some investors are also reacting to news of potential partnerships for weight-loss drug delivery, while others express frustration with the stock's recent performance.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is trending as investors are closely watching for potential asset sales and a possible foreign partnership, highlighted by a recent Memorandum of Understanding with a major global steel producer. Community discussions revolve around the impact of this MoU and potential buyout scenarios, alongside the company's strategic position in the US steel market. Additionally, tariffs and macro data surrounding the steel and automotive industries remain key talking points for CLF.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is trending due to increased 2025 revenue guidance driven by strong DefenCath sales and the Melinta portfolio. The community is discussing the raised guidance and potential for further growth, with some expressing excitement about the company's future prospects. Broader discussions include CorMedix's strategic investment in Talphera and potential impacts of upcoming clinical data.

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Celcuity Inc

CELC is trending following positive Phase 3 breast cancer trial data, which has sparked significant community discussion about potential FDA approval and a possible buyout. Bullish sentiment is fueled by analysts increasing price targets, while some traders are wary of potential dilution and an overextended valuation. The community is actively debating the stock's near-term direction and long-term potential in the breast cancer treatment landscape.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending as investors digest news of Tim Cook pledging to boost investments in China amidst trade tension concerns. Upgrades to the M5 chip, along with new MacBook and iPad Pro models, are also fueling bullish sentiment, while some analysts believe Apple needs to bolster its AI capabilities to compete with other tech giants like Meta. Community members are actively discussing the stock's potential to reach new highs, with some expressing concerns about overvaluation and dependence on China.

NuCana Plc is a clinical stage biopharmaceutical company. It engages in the business of developing a portfolio of new medicines to treat patients with cancer. The company was founded by Hugh Stephen Griffith and Christopher Barry Wood on January 28, 1997 and is headquartered in Edinburgh, the United Kingdom.

NuCana plc - ADR

NuCana plc

NCNA is trending due to encouraging data releases and regulatory approvals regarding their oncology assets, sparking optimism within the community. Bullish investors are actively discussing the potential for significant price appreciation, fueled by the company's compelling early efficacy in chemo-resistant settings. Some traders are drawing comparisons to other low floaters and anticipating a large move, highlighting the upcoming presentation at the ESMO congress.

Solana Co. is a neurotech company in the medical device industry that focuses on neurological wellness. The firm develops, licenses and acquires non-invasive platform technologies that amplify the brain’s ability to heal itself and reduce symptoms of neurological disease or trauma. It engages in the development of the investigational portable neuromodulation stimulator, that delivers neurostimulation via the tongue which has been shown in clinical studies to enhance the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury. The company was founded on March 13, 2014 and is headquartered in Newtown, PA.

Solana Co. - Ordinary Shares - Class A

Solana Co

HSDT is trending due to news of a significant funding round aimed at establishing a Solana-backed treasury, sparking excitement about its potential as a crypto play. The community is actively debating whether this move will be a game-changer or a dilution trap, with some drawing comparisons to other companies with crypto treasuries. Many traders are watching the stock's correlation with Solana ($SOL) and anticipating further volatility.

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.

GRAIL Inc.

GRAIL is trending due to promising data from its PATHFINDER 2 study, highlighting the potential of its Galleri multi-cancer early detection test; the study results pave the way for FDA submission. Community members are discussing the potential for Medicare coverage and revenue growth, especially with support in Congress, and Samsung's commitment to marketing in Asia. The company is also presenting at the Jefferies Global Healthcare Conference on Wednesday.

Bakkt Holdings, Inc. engages in the intersection of cryptoassets, loyalty and rewards, and payments. It also provides a platform to expand payment offerings, create new revenue streams, and increase customer loyalty. The company was founded in 2018 and is headquartered in New York, NY.

Bakkt Holdings Inc - Ordinary Shares - Class A

Bakkt Holdings Inc

BKKT is trending as community members discuss its potential for further gains, driven by renewed crypto optimism and the recent appointment of a new board member. BlackRock's increased stake in the company is fueling bullish sentiment, while others point to a potential short squeeze. Discussions also center on the company's simplified corporate structure and its implications for institutional investment.

Blue Owl Capital, Inc. operates as an alternative asset management firm. It provides investors access to asset management capital solutions through its Direct Lending and GP Capital Solutions products. The company offers a platform of capital solutions to both middle market companies and large alternative asset managers. The company was founded by Doug Irving Ostrover, Michael Rees and Craig W.Packer in 2009 and is headquartered in New York, NY.

Blue Owl Capital Inc - Ordinary Shares - Class A

OWL is trending due to growing interest in its involvement in financing AI data centers, including a significant deal with Meta. The community is discussing the company's partnerships and potential for growth in the alternative asset management sector, with some analysts issuing positive ratings and price targets. Additionally, Blue Owl's management is actively defending against credit quality concerns and highlighting its strengths in the current economic environment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Celcuity Inc. (CELC) stock surged about 221% on Monday morning after the company announced that its experimental combination treatment demonstrated a reduction in the risk of disease progression or death in patients with a type of advanced breast cancer in a late-stage study.The firm <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.celcuity.com/press-releases/">said</a> that the combination of Gedatolisib, Fulvestrant, and Palbociclib reduced the risk of disease progression or death by 76% compared to Fulvestrant alone in patients with previously treated HR+/HER2- advanced breast cancer.Median progression-free survival was 9.3 months with the Gedatolisib triplet compared to two months with Fulvestrant alone, meaning patients lived an average of 9.3 months without progression of disease with the treatment.A combination of Gedatolisib plus Fulvestrant reduced the risk of disease progression or death by 67% compared to Fulvestrant, with a median progression-free survival of 7.4 months.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/CELC">Celcuity</a> trended in the ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:625/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_28_at_9_01_25_AM_png_aec1ab2846.webp" alt="CELC's Sentiment Meter and Message Volume as of 9 a.m. ET on July 28, 2025 | Source: Stocktwits" width="625" height="61"><figcaption>CELC's Sentiment Meter and Message Volume as of 9 a.m. ET on July 28, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that they expect a peak market valuation of three to five billion dollars for the company.<stembedurl>https://stocktwits.com/BIOTECH_GURU/message/622681433</stembedurl>Another said that the news is worth at least a 500% rally.<stembedurl>https://stocktwits.com/madape/message/622680399</stembedurl> Breast cancer is the second most common cancer and one of the leading causes of cancer-related deaths worldwide. According to Celcuity, HR+/HER2- breast cancer is the most common subtype of breast cancer, accounting for approximately 70% of all breast cancers.The improvements in progression-free survival observed in the study with the combinations were statistically significant and clinically meaningful, the company said.Both the combinations were better tolerated than observed in an early-stage trial in patients with advanced breast cancer, it added.Sara Hurvitz, co-principal investigator for the trial, said that the data for both combination treatments in the trials are “potentially practice-changing.”“The efficacy improvement relative to the control that each of the gedatolisib regimens demonstrated was historic for this patient population,” CEO Brian Sullivan added.Celcuity expects to submit a new drug application for Gedatolisib to the U.S. Food and Drug Administration in the fourth quarter of 2025.CELC stock is up by about 238% this year and by 147% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/weride-receives-autnomous-driving-permit-in-saudi-arabia/choeFojR5Dy">WeRide Receives Autonomous Driving Permit in Saudi Arabia: Retail Sees Stock Hitting $20</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

This Pharma Stock Rose 200% On Monday Morning And Retail Says Valuation Could Rise To $5B: Here’s Why

Sara Hurvitz, co-principal investigator for the trial, said that the data for both combination treatments in the trials are “potentially practice-changing.”

Equity

Sara Hurvitz, co-principal investigator for the trial, said that the data for both combination treatments in the trials are “potentially practice-changing.”


Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032

Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032 Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032 PR Newswire VANCOUVER...

Celcuity To Present at Upcoming Needham and Stifel Investor Conferences

MINNEAPOLIS, April 04, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that...

Celcuity Inc.'s (NASDAQ:CELC) large institutional owners must be happy as stock continues to impress, up 12% over the past week

Key Insights Institutions' substantial holdings in Celcuity implies that they have significant influence over the...

Celcuity (NASDAQ:CELC) Price Target Increased to $24.00 by Analysts at Needham & Company LLC

Celcuity (NASDAQ:CELC - Free Report) had its price target hoisted by Needham  Company LLC from $23.00 to $24.00 in a research report released on Thursday, Benzinga reports. Needham  Company...

Celcuity (NASDAQ:CELC - Get Free Report) had its price objective increased by equities researchers at Needham & Company LLC from $23.00 to $24.00 in a research report issued to clients and investors...

Celcuity (NASDAQ:CELC) Given New $25.00 Price Target at Craig Hallum

Celcuity (NASDAQ:CELC  Free Report) had its target price lifted by Craig Hallum from $20.00 to $25.00 in a report issued on Thursday morning, Benzinga reports. The firm currently has a buy...

Celcuity Inc.'s Balancing Act: Navigating Financial Risks in Capital Raising Endeavors

Celcuity Inc. (CELC) has disclosed a new risk, in the Share Price & Shareholder Rights category. Celcuity Inc. faces significant financial risks as...

Celcuity (CELC, $21.58) RSI Indicator left the overbought zone on March 28, 2024

This is a signal that CELC's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

Celcuity (CELC, $21.58) Moving Average Convergence Divergence (MACD) Histogram turned positive on March 28, 2024

This is a Bullish indicator signaling CELC's price could rise from here. Traders may explore going long the stock or buying call options...

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Netflix Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits Polls

CELC is trending due to positive Phase 3 trial data for its breast cancer therapy, gedatolisib, showing a significant reduction in disease progression risk, leading to community excitement and analyst upgrades. The community is discussing the potential for FDA approval, buyout scenarios, and the impact on treatment standards, while also noting the possibility of a near-term offering. However, some caution against shorting and potential overvaluation, recognizing the strong positive data, while others suggest a pullback is imminent.

CELC
Celcuity Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest CELC News

CELCCelcuity Inc